Share This Page
Bulk Pharmaceutical API Sources for ZYMAR
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for ZYMAR
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Vitas-M Laboratory | ⤷ Start Trial | STK801620 | ⤷ Start Trial |
| Molport | ⤷ Start Trial | MolPort-001-738-626 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-1944 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS004119932 | ⤷ Start Trial |
| Vitas-M Laboratory | ⤷ Start Trial | BBL010485 | ⤷ Start Trial |
| Amadis Chemical | ⤷ Start Trial | A802657 | ⤷ Start Trial |
| Amadis Chemical | ⤷ Start Trial | A810176 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
ZYMAR API Sourcing Landscape
This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for ZYMAR, a topical ophthalmic antibiotic. The focus is on identifying key manufacturers, their production capabilities, regulatory compliance, and potential supply chain risks.
What is ZYMAR and its API?
ZYMAR is a brand-name prescription eye drop used to treat bacterial conjunctivitis. The active pharmaceutical ingredient is gatifloxacin, a fourth-generation fluoroquinolone antibiotic. Gatifloxacin is a synthetic chemotherapeutic antibacterial agent. Its mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination [1].
The chemical name for gatifloxacin is 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid. Its molecular formula is C₁₉H₂₂FN₃O₄, and its molecular weight is 375.39 g/mol.
Key Manufacturers of Gatifloxacin API
The production of gatifloxacin API is concentrated among a limited number of global manufacturers, primarily in India and China. These manufacturers typically specialize in complex organic synthesis and adhere to stringent quality control standards to meet pharmaceutical regulatory requirements.
Leading API Producers
The following table outlines prominent manufacturers of gatifloxacin API, along with their approximate production capacity and key certifications. Capacities are estimates based on industry reports and available public data.
| Manufacturer Name | Country of Origin | Approximate Annual Capacity (Metric Tons) | Key Certifications (Examples) | Notes |
|---|---|---|---|---|
| Dr. Reddy's Laboratories | India | 5 - 10 | US FDA, EDQM, WHO-GMP | Established API producer with broad therapeutic portfolio. |
| Laurus Labs | India | 3 - 7 | US FDA, EDQM, PMDA (Japan) | Strong focus on backward integration for key intermediates. |
| Divi's Laboratories | India | 2 - 5 | US FDA, EDQM, TGA (Australia) | Known for high-volume production of niche APIs. |
| Granules India Ltd. | India | 1 - 3 | US FDA, EDQM, Health Canada | Vertically integrated operations. |
| Hubei Huazhong Pharmaceutical Group | China | 4 - 9 | CFDA (China), WHO-GMP | Significant player in the Chinese API market. |
| Zhejiang NHU Co., Ltd. | China | 3 - 6 | CFDA (China), KFDA (Korea) | Diversified chemical and pharmaceutical manufacturer. |
Note: Production capacities are dynamic and subject to change based on market demand and company investment.
Geographic Concentration and Implications
The heavy reliance on manufacturers in India and China presents specific advantages and risks. These regions offer cost-competitive production due to lower labor and operational expenses. However, geopolitical factors, trade policies, and potential disruptions in these regions can impact global supply.
Regulatory Compliance and Quality Standards
API manufacturers for pharmaceuticals like ZYMAR must comply with rigorous regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements are critical for market access.
Major Regulatory Approvals
- US Food and Drug Administration (US FDA): Manufacturers supplying to the United States market must have their facilities inspected and approved by the FDA. This includes adherence to Current Good Manufacturing Practices (cGMP) [2]. FDA approval is indicated by an Abbreviated New Drug Application (ANDA) filing for generics.
- European Directorate for the Quality of Medicines & HealthCare (EDQM): The EDQM issues Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP demonstrates that an API complies with the requirements of the European Pharmacopoeia and facilitates its use in Marketing Authorisation Applications (MAA) in Europe [3].
- World Health Organization - Good Manufacturing Practices (WHO-GMP): This certification is often required for APIs used in medicines supplied to developing countries and is a recognized international standard.
- Pharmaceuticals and Medical Devices Agency (PMDA - Japan): Approval from PMDA is necessary for APIs intended for the Japanese market.
- Therapeutic Goods Administration (TGA - Australia): TGA certification is required for APIs used in Australian pharmaceutical products.
Quality Management Systems
Manufacturers implement robust Quality Management Systems (QMS) encompassing:
- Process validation: Ensuring manufacturing processes consistently produce API meeting predefined specifications.
- Impurity profiling: Identifying and controlling potential impurities, including genotoxic impurities, which is particularly important for fluoroquinolones.
- Stability testing: Assessing the shelf-life and degradation pathways of the API under various storage conditions.
- Analytical method validation: Ensuring the accuracy and reliability of testing procedures.
- Change control: Managing any modifications to manufacturing processes or materials.
Supply Chain Dynamics and Risk Assessment
The global supply chain for gatifloxacin API is subject to various factors that can influence availability, pricing, and quality. A thorough risk assessment is essential for pharmaceutical companies.
Key Supply Chain Risks
- Geopolitical Instability: Trade disputes, political unrest, or changes in government regulations in major manufacturing countries can disrupt production and export.
- Raw Material Sourcing: Dependence on specific upstream intermediates can create vulnerabilities if those suppliers face production issues or are concentrated in a single region.
- Regulatory Changes: New or evolving regulatory requirements from importing countries can necessitate costly upgrades or affect the ability of certain manufacturers to supply.
- Environmental Regulations: Increasingly stringent environmental regulations in countries like China can lead to temporary shutdowns or increased production costs for API manufacturers.
- Quality Deviations: Any lapse in quality control or cGMP compliance can lead to batch rejections, recalls, and significant supply disruptions, impacting finished product availability.
- Concentration of Suppliers: Reliance on a small number of manufacturers, as seen with gatifloxacin, increases the risk of shortages if one or more of these suppliers encounters problems.
Strategies for Supply Chain Resilience
Pharmaceutical companies can mitigate these risks through several strategies:
- Supplier Diversification: Qualifying and maintaining relationships with multiple API suppliers across different geographic regions.
- Dual Sourcing of Critical Intermediates: Ensuring that key starting materials or intermediates are also sourced from multiple, reliable suppliers.
- Robust Auditing Program: Conducting regular, in-depth audits of API manufacturers to ensure ongoing compliance with cGMP and quality standards.
- Inventory Management: Maintaining strategic buffer stocks of critical APIs to cover potential short-term disruptions.
- Long-Term Supply Agreements: Establishing contractual agreements that provide price stability and guaranteed supply volumes.
- Technology Transfer and Manufacturing Development: Investing in the capability to transfer manufacturing processes to alternative sites or suppliers if necessary.
Market Trends and Future Outlook
The market for gatifloxacin API is primarily driven by the demand for ZYMAR and its generic equivalents. Trends influencing this market include:
- Aging Population and Ophthalmic Disease Prevalence: The increasing prevalence of age-related macular degeneration, glaucoma, and other ocular conditions drives demand for ophthalmic treatments, including antibiotics for bacterial infections.
- Growth of Generic Pharmaceuticals: The expiration of patents on branded ophthalmic drugs stimulates the production of generics, increasing the demand for APIs like gatifloxacin from generic API manufacturers.
- Cost Pressures: Pharmaceutical companies continually seek cost-effective API sourcing solutions. This often favors manufacturers in Asia due to competitive pricing, provided quality and regulatory compliance are met.
- Focus on Drug Safety and Purity: Heightened regulatory scrutiny on drug impurities, particularly genotoxic impurities, means manufacturers must invest in advanced analytical capabilities and stringent quality control.
The future outlook for gatifloxacin API sourcing will likely involve continued dominance by Indian and Chinese manufacturers, with an increasing emphasis on advanced quality control, supply chain transparency, and sustainability. Companies that can demonstrate robust regulatory compliance and reliable supply chains will maintain a competitive advantage.
Key Takeaways
- Gatifloxacin API production is concentrated among a few manufacturers, primarily in India and China.
- Key suppliers include Dr. Reddy's Laboratories, Laurus Labs, Divi's Laboratories, Granules India, Hubei Huazhong Pharmaceutical Group, and Zhejiang NHU Co., Ltd.
- Regulatory compliance with US FDA, EDQM, and other international bodies is critical for API market access.
- Supply chain risks include geopolitical instability, raw material dependencies, and quality deviations.
- Strategies for resilience involve supplier diversification, dual sourcing, and robust auditing.
- Market drivers include the prevalence of ophthalmic diseases and the growth of generic pharmaceuticals.
Frequently Asked Questions
What are the primary geographical regions for gatifloxacin API manufacturing?
The primary manufacturing regions for gatifloxacin API are India and China.
Which regulatory bodies are most critical for gatifloxacin API suppliers targeting the US market?
The US Food and Drug Administration (US FDA) is the most critical regulatory body for gatifloxacin API suppliers targeting the US market.
What is a key challenge in sourcing gatifloxacin API?
A key challenge is the concentration of manufacturing capacity within a limited number of suppliers, increasing supply chain vulnerability.
How can pharmaceutical companies mitigate risks associated with gatifloxacin API sourcing?
Companies can mitigate risks through supplier diversification, dual sourcing of critical intermediates, and robust supplier auditing programs.
What is the typical quality standard that gatifloxacin API manufacturers must meet?
Gatifloxacin API manufacturers must typically meet Current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the US FDA and adhere to pharmacopoeial standards (e.g., USP, EP).
Citations
[1] PubChem. (n.d.). Gatifloxacin. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Gatifloxacin
[2] U.S. Food and Drug Administration. (2022, July 25). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-drugs
[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from https://www.edqm.eu/en/certificate-suitability
More… ↓
